Article Information
vol. 29 no. 156
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 13, 2020
- Accepted April 6, 2020
- Published online May 15, 2020.
Copyright & Usage
Copyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- 1Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
- 2Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
- 3Insigneo Institute for in silico medicine, University of Sheffield, Sheffield, UK
- David G. Kiely, Sheffield Pulmonary Vascular Disease Unit, Room M15, Ward M2, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK. E-mail: david.kiely1{at}nhs.net
Funding
Janssen Ltd
Article usage
Altmetrics
Vol 29 Issue 156
Table of Contents
BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Physiology of natriuretic peptides and the role of BNP and NT-proBNP in cardiovascular disease and PAH
- BNP/NT-proBNP and comparison with pulmonary haemodynamics, echocardiographic and CMR metrics
- Risk stratification in PAH and the role of BNP/NT-proBNP
- Screening for PAH in systemic sclerosis
- BNP and NT-proBNP considerations for sampling
- Comparison of BNP and NT-proBNP as biomarkers in the clinical setting
- Point-of-care testing: what opportunities are there to improve patient outcomes in patients with PAH?
- What do we need to know before introducing POCT to PAH assessment?
- Conclusion
- Acknowledgements
- Footnotes
- References
- Figures & Data
- Info & Metrics